Neuphoria Therapeutics Inc. (NEUP)
Data as of , from SEC Form 4 filings.
See up to 3 months of NEUP. The 7-day demo opens the 1M and 3M ranges and puts NEUP on your watchlist.
Start 7-day demoLatest NEUP insider trades
- Lynx1 Capital Management LP - 10% OwnerOpen-market purchase$3.28M
David Ian Wilson - DirectorGrant or award8,537 sh- Peter Miles Winston Davies
About Neuphoria Therapeutics Inc. (NEUP)
Neuphoria Therapeutics Inc. files with the SEC under CIK 0001191070 and is classified as pharmaceutical preparations. It is grouped with Health Care companies on this site.
NEUP Form 4 activity by transaction type, last 90 days
No Form 4 activity for NEUP in the last 90 days.
NEUP insider transactions (Form 4)
1111 Form 4 filings on record, the earliest from Apr 16, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| David Ian Wilson - Director | Grant or award | Restricted Stock Units | 8,537 | $0.00 | - | |
| Peter Miles Winston Davies - Director | Grant or award | Restricted Stock Units | 8,537 | $0.00 | - | |
| Alan Fisher - Director | Grant or award | Restricted Stock Units | 17,073 | $0.00 | - | |
| Jane Ryan - Director | Grant or award | Restricted Stock Units | 8,537 | $0.00 | - | |
| Lynx1 Capital Management LP - 10% Owner | Open-market purchase | Common stock, $0.00001 par value per share | 639,110 | $5.14 footnote F1 | $3.28M | |
| ||||||
 Spyros Papapetropoulos - Officer | Grant or award | Employee Stock Option (Right-to- Buy) | 34,559 | $8.27 | $286K | |
| Peter Miles Winston Davies - Director | Grant or award | Restricted Stock Units | 6,783 | $0.00 | - | |
| Jane Ryan - Director | Grant or award | Restricted Stock Units | 6,783 | $0.00 | - | |
| David Ian Wilson - Director | Grant or award | Restricted Stock Units | 6,783 | $0.00 | - | |
| Alan Fisher - Director | Grant or award | Restricted Stock Units | 13,566 | $0.00 | - | |
| Spyros Papapetropoulos - Officer | Grant or award | Employee Stock Option (Right-to-Buy) | 27,000 | $5.16 | $139K | |
NEUP insider trading FAQ
What is the latest insider trade for NEUP?
Neuphoria Therapeutics Inc. (NEUP) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-01-21. The full record for NEUP runs to 11 Form 4 filings, the earliest from 2025-04-16. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying NEUP stock?
No insider purchases of NEUP were filed in the last 90 days. 1 purchase is on record for this company.
How many insiders are selling NEUP stock?
No insider sales of NEUP were filed in the last 90 days.
Where can I see NEUP SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects NEUP Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - David Ian Wilson view on EDGAR
- - Peter Miles Winston Davies view on EDGAR
- - Alan Fisher view on EDGAR
- - Jane Ryan view on EDGAR
- - Lynx1 Capital Management LP view on EDGAR
- - Spyros Papapetropoulos view on EDGAR
- - Peter Miles Winston Davies view on EDGAR
- - Jane Ryan view on EDGAR
- - David Ian Wilson view on EDGAR
- - Alan Fisher
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where NEUP's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow NEUP with a 7-day demo
- NEUP on your watchlist
- Every NEUP Form 4 filing on record
- Up to 3 months of NEUP price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
